Shares of Indaptus Therapeutics Inc. nearly tripled on massive volume in midday trading, to bounce off the previous session’s record closing low, after the developer of treatments for hepatitis and HIV announced the allowance of a patent for its platform technology. The stock was up as much as 307.8% at a six-month high of $28.83 before paring gains to be up 184.3%. Trading volume exploded to 119.2 million shares, compared with the full-day average of just 227,600 shares. The stock was the biggest gainer and third-most active on major U.S. exchanges. The company said before the open that its patent titled “Methods of Treatment of Infections Using Bacteria,” provides broad protection for the application of the company’s platform technology alone and in combination with standards of care for the treatment and inhibition of hepatitus B virus and human immunodeficiency virus (HIV) infections. “This notice of allowance gives us the optionality to confidently pursue our technology in viral diseases and/or to partner it for further development,” said Chief Executive Jeffrey Meckler. The stock has now gained 45.7% year to date, while the iShares Biotechnology ETF has tacked on 13.2% and the S&P 500 has advanced 19.0%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
- Brett Arends’s ROI: The nursing home crisis is ‘worse than ever’ - September 22, 2021
- Better Being abandons IPO plans - September 22, 2021
- Dow industrials stake out 200-point gain early Wednesday - September 22, 2021